title: Time toAkt: Superior tumor-reactive T cells for adoptive immunotherapy.
abstract: T cells are crucial players in the protection against cancer, and can be used in adoptive cell therapy to prevent or treat relapse. However, their state of differentiation determines their effectiveness, with early memory cells being the most favorable. Here, we discuss restraining of differentiation to engineer the ultimate tumor-reactive T cell.
authors.affiliation: Department of Laboratory Medicine - Laboratory of Hematology; Radboud university medical center ; Nijmegen, The Netherlands.
authors.forename: Anniek B
authors.initials: AB
authors.lastname: van der Waart
authors.affiliation: Department of Laboratory Medicine - Laboratory of Hematology; Radboud university medical center ; Nijmegen, The Netherlands.
authors.forename: Willemijn
authors.initials: W
authors.lastname: Hobo
authors.affiliation: Department of Laboratory Medicine - Laboratory of Hematology; Radboud university medical center ; Nijmegen, The Netherlands.
authors.forename: Harry
authors.initials: H
authors.lastname: Dolstra
keywords: ACT: adoptive cell therapy; APC: antigen-presenting cells; Akt; Allo-SCT: allogeneic stem cell transplantation; CAR: chimeric antigen receptor; DCs: dendritic cells; IL-15; IL-7; MiHAs: minor histocompatibility antigens; T-cell differentiation; TCR: T-cell receptor; TILs: tumor-infiltrating lymphocytes; Tcm: central memory T; Teff: effector T; Tem: effector memory T; Tn: naive T; Tscm: stem cell memory T; Wnt; adoptive T cell therapy; dendritic cell; stem cell transplantation